New drug combo shows promise in early cancer trial
NCT ID NCT04649385
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new drug called BGB-15025, alone or with another drug (tislelizumab), in 157 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study is now complete, and results will help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BGB-15025 (HPK1 inhibitor) and tislelizumab (anti-PD-1 antibody)
What this could lead to
If successful, this could lead to a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if the drug works. Side effects are possible, and the drug may not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
SongpaGu, Seoul Teugbyeolsi, 05505, South Korea
-
Ashford Cancer Centre Research Northeast
Windsor Gardens, South Australia, SA 5087, Australia
-
Auckland City Hospital
Auckland, 1023, New Zealand
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150000, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Icahn School of Medicine At Mount Sinai
New York, New York, 10029-6504, United States
-
Linear Clinical Research
Nedlands, Western Australia, WA 6009, Australia
-
Peter Maccallum Cancer Centre
Melbourne, Victoria, VIC 3000, Australia
-
Prince of Wales Hospital
Randwick, New South Wales, NSW 2031, Australia
-
Samsung Medical Center
GangnamGu, Seoul Teugbyeolsi, 06351, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620, South Korea
-
Severance Hospital Yonsei University Health System
SeodaemunGu, Seoul Teugbyeolsi, 03722, South Korea
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310016, China
-
The Catholic University of Korea, Seoul St Marys Hospital
SeochoGu, Seoul Teugbyeolsi, 06591, South Korea
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
The University of Texas Md Anderson Cancer Center
Houston, Texas, 77030-4009, United States
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Ut Health San Antonio Mays Cancer Center
San Antonio, Texas, 78229-4427, United States
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China